Financial RiskRisks include inability to resubmit the tab-cel BLA in a timely manner, rejection of the tab-cel BLA resubmission by the FDA, and setbacks with other pipeline candidates.
Regulatory SetbacksInitial BLA was rejected by FDA due to a third-party manufacturing issue, without request for additional clinical data.
Workforce ReductionsAtara announced a reduction in its workforce that will impact approximately 50% of its current employees.